These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 2056139)

  • 1. CNS stimulant potentiation of monoamine oxidase inhibitors in treatment-refractory depression.
    Fawcett J; Kravitz HM; Zajecka JM; Schaff MR
    J Clin Psychopharmacol; 1991 Apr; 11(2):127-32. PubMed ID: 2056139
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined MAOI, TCA, and direct stimulant therapy of treatment-resistant depression.
    Feighner JP; Herbstein J; Damlouji N
    J Clin Psychiatry; 1985 Jun; 46(6):206-9. PubMed ID: 3997787
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Addition of monoamine oxidase inhibitors to carbamazepine: preliminary evidence of safety and antidepressant efficacy in treatment-resistant depression.
    Ketter TA; Post RM; Parekh PI; Worthington K
    J Clin Psychiatry; 1995 Oct; 56(10):471-5. PubMed ID: 7559374
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low-dose trazodone as a hypnotic in patients treated with MAOIs and other psychotropics: a pilot study.
    Jacobsen FM
    J Clin Psychiatry; 1990 Jul; 51(7):298-302. PubMed ID: 2365668
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current prescription patterns and safety profile of irreversible monoamine oxidase inhibitors: a population-based cohort study of older adults.
    Shulman KI; Fischer HD; Herrmann N; Huo CY; Anderson GM; Rochon PA
    J Clin Psychiatry; 2009 Dec; 70(12):1681-6. PubMed ID: 19852903
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment response of depressed outpatients unresponsive to both a tricyclic and a monoamine oxidase inhibitor antidepressant.
    McGrath PJ; Stewart JW; Nunes EN; Quitkin FM
    J Clin Psychiatry; 1994 Aug; 55(8):336-9. PubMed ID: 8071301
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Combined therapy with tricyclic and MAOI antidepressants in the treatment of resistant major depression].
    Rosan TA; Mesones HL; Brengio F
    Acta Psiquiatr Psicol Am Lat; 1994 Dec; 40(4):314-20. PubMed ID: 7484185
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bipolar depression: treatment options.
    Yatham LN; Kusumakar V; Parikh SV; Haslam DR; Matte R; Sharma V; Kennedy S
    Can J Psychiatry; 1997 Aug; 42 Suppl 2():87S-91S. PubMed ID: 9288441
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The use of monoamine oxidase inhibitors in primary care.
    Culpepper L
    J Clin Psychiatry; 2012; 73 Suppl 1():37-41. PubMed ID: 22951241
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combining stimulants with monoamine oxidase inhibitors: a review of uses and one possible additional indication.
    Feinberg SS
    J Clin Psychiatry; 2004 Nov; 65(11):1520-4. PubMed ID: 15554766
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Refractory depression treated with high doses of monoamine oxidase inhibitor.
    Guze BH; Baxter LR; Rego J
    J Clin Psychiatry; 1987 Jan; 48(1):31-2. PubMed ID: 3804984
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Divalproex sodium in the treatment of refractory affective disorders.
    Schaff MR; Fawcett J; Zajecka JM
    J Clin Psychiatry; 1993 Oct; 54(10):380-4. PubMed ID: 8262880
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug therapy reviews: tricyclic antidepressant and monoamine oxidase inhibitor combination therapy.
    Ponto LB; Perry PJ; Liskow BI; Seaba HH
    Am J Hosp Pharm; 1977 Sep; 34(9):954-61. PubMed ID: 333909
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rational polypharmacy in the bipolar affective disorders.
    Post RM; Ketter TA; Pazzaglia PJ; Denicoff K; George MS; Callahan A; Leverich G; Frye M
    Epilepsy Res Suppl; 1996; 11():153-80. PubMed ID: 9294735
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Elderly patients, classical monoamine oxidase inhibitors and intercurrent somatic diseases].
    Oostervink F; Bouvy PF; Touw DJ
    Ned Tijdschr Geneeskd; 2003 Oct; 147(40):1937-40. PubMed ID: 14574773
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reversible monoamine oxidase-A inhibitors in resistant major depression.
    Nolen WA; Hoencamp E; Bouvy PF; Haffmans PM
    Clin Neuropharmacol; 1993; 16 Suppl 2():S69-76. PubMed ID: 8313400
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pergolide: an antidepressant adjuvant for mood disorders?
    Bouckoms A; Mangini L
    Psychopharmacol Bull; 1993; 29(2):207-11. PubMed ID: 8290667
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adverse consequences of fluoxetine-MAOI combination therapy.
    Feighner JP; Boyer WF; Tyler DL; Neborsky RJ
    J Clin Psychiatry; 1990 Jun; 51(6):222-5. PubMed ID: 2347858
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Using antipsychotic agents in older patients.
    Alexopoulos GS; Streim J; Carpenter D; Docherty JP;
    J Clin Psychiatry; 2004; 65 Suppl 2():5-99; discussion 100-102; quiz 103-4. PubMed ID: 14994733
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Do the old psychostimulant drugs have a role in managing treatment-resistant depression?
    Parker G; Brotchie H
    Acta Psychiatr Scand; 2010 Apr; 121(4):308-14. PubMed ID: 19594481
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.